122 related articles for article (PubMed ID: 16516125)
1. Autologous immune strategies to reduce the risk of leukemic relapse: consideration for IL-15.
Blaser BW; Caligiuri MA
Best Pract Res Clin Haematol; 2006; 19(2):281-92. PubMed ID: 16516125
[TBL] [Abstract][Full Text] [Related]
2. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy by allogeneic stem cell transplantation.
Ringdén O
Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
[TBL] [Abstract][Full Text] [Related]
4. The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease.
Kim SY; Lee DG; Kim MS; Kim HJ; Lee S; Min CK
Am J Hematol; 2008 Oct; 83(10):784-8. PubMed ID: 18661492
[TBL] [Abstract][Full Text] [Related]
5. Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation.
Parkman R; Cohen G; Carter SL; Weinberg KI; Masinsin B; Guinan E; Kurtzberg J; Wagner JE; Kernan NA
Biol Blood Marrow Transplant; 2006 Sep; 12(9):919-27. PubMed ID: 16920557
[TBL] [Abstract][Full Text] [Related]
6. Nonleukemic myeloid dendritic cells obtained from autologous stem cell products elicit antileukemia responses in patients with acute myeloid leukemia.
Serrano-López J; Sanchez-Garcia J; Serrano J; Alvarez-Rivas MA; Garcia-Castellano JM; Roman-Gomez J; de la Rosa O; Herrera-Arroyo C; Torres-Gomez A
Transfusion; 2011 Jul; 51(7):1546-55. PubMed ID: 21303373
[TBL] [Abstract][Full Text] [Related]
7. Antileukemic immunity associated with antineutrophil antibody production after allogeneic hematopoietic SCT for myeloid/NK-cell precursor acute leukemia.
Suzuki H; Suzuki T; Kamijo A; Oota S; Sato H; Hangaishi A; Takahashi T; Kanda Y; Motokura T; Chiba S; Kurokawa M
Bone Marrow Transplant; 2008 Aug; 42(4):285-7. PubMed ID: 18500367
[No Abstract] [Full Text] [Related]
8. [Allogeneic stem cell transplantation in the management of acute myeloid leukemia].
Schmid C; Kolb HJ
Med Klin (Munich); 2007 Apr; 102(4):317-23. PubMed ID: 17426935
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in allogeneic hematopoietic stem cell transplantation--not just a case for effector cells.
Troeger A; Meisel R; Moritz T; Dilloo D
Bone Marrow Transplant; 2005 Mar; 35 Suppl 1():S59-64. PubMed ID: 15812533
[TBL] [Abstract][Full Text] [Related]
10. Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation.
Schulze A; Schirutschke H; Oelschlägel U; Schmitz M; Füssel M; Wassmuth R; Ehninger G; Bornhäuser M; Platzbecker U
Exp Hematol; 2008 Apr; 36(4):378-89. PubMed ID: 18261840
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplantation in acute myeloid leukemia: a risk-adapted approach.
Lodewyck T; Cornelissen JJ
Blood Rev; 2008 Nov; 22(6):293-302. PubMed ID: 18455284
[TBL] [Abstract][Full Text] [Related]
12. An Hsp70 peptide initiates NK cell killing of leukemic blasts after stem cell transplantation.
Gross C; Holler E; Stangl S; Dickinson A; Pockley AG; Asea AA; Mallappa N; Multhoff G
Leuk Res; 2008 Apr; 32(4):527-34. PubMed ID: 17543383
[TBL] [Abstract][Full Text] [Related]
13. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
Thorén FB; Romero AI; Brune M; Hellstrand K
Expert Opin Biol Ther; 2009 Sep; 9(9):1217-23. PubMed ID: 19653866
[TBL] [Abstract][Full Text] [Related]
14. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.
Loren AW; Porter DL
Bone Marrow Transplant; 2008 Mar; 41(5):483-93. PubMed ID: 18026156
[TBL] [Abstract][Full Text] [Related]
15. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
16. Graft-versus-disease effect following allogeneic transplantation for acute leukaemia.
Rowe JM
Best Pract Res Clin Haematol; 2008 Sep; 21(3):485-502. PubMed ID: 18790451
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels.
Boyiadzis M; Memon S; Carson J; Allen K; Szczepanski MJ; Vance BA; Dean R; Bishop MR; Gress RE; Hakim FT
Biol Blood Marrow Transplant; 2008 Mar; 14(3):290-300. PubMed ID: 18275895
[TBL] [Abstract][Full Text] [Related]
18. Donor leukocyte infusions in myeloid malignancies: new strategies.
Porter DL; Antin JH
Best Pract Res Clin Haematol; 2006; 19(4):737-55. PubMed ID: 16997180
[TBL] [Abstract][Full Text] [Related]
19. Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience.
Martins C; Lacerda JF; Lourenço F; Carmo JA; Lacerda JM
Acta Med Port; 2005; 18(5):329-37. PubMed ID: 16611537
[TBL] [Abstract][Full Text] [Related]
20. Stem-cell transplantation in chronic lymphocytic leukaemia.
Gribben JG
Best Pract Res Clin Haematol; 2007 Sep; 20(3):513-27. PubMed ID: 17707837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
